Antibody Purification via pH Adjustment for HCP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reducing host cell proteins (HCPs) in therapeutic or diagnostic protein preparations are inefficient, leading to incomplete removal, aggregation, immunogenicity concerns, and increased manufacturing costs, with limitations in applicability to specific molecules and formats.
Innovation Solution
A method involving affinity chromatography with a buffer combination of weak and strong acids, followed by pH adjustment and depth filtration, effectively reduces HCPs to very low levels (<1 ppm) without affecting protein stability or yield, and is applicable to a broad range of molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used to remove HCPs, then HCP removal is achieved, but additional purification steps are required resulting in reduced yield and increased manufacturing costs
Solution Approach 1:
The invention combines HCP removal and virus inactivation into a single integrated step by adjusting the pH of the eluate to below pH 4.0 after affinity chromatography. This dual-function approach eliminates the need for separate purification steps, thereby maintaining manufacturing yield while reducing costs and achieving effective HCP removal.
Solution Approach 2:
The invention utilizes pH adjustment as a critical parameter change to achieve both HCP removal and virus inactivation. By lowering the pH to below 4.0, the method creates conditions that simultaneously denature HCPs and inactivate viruses, while the antibody remains stable due to its specific pH resilience characteristics.
2Manufacturing precision
If additional purification steps are added to reduce HCPs, then HCP content is reduced, but product aggregation and immunogenicity risks increase
Solution Approach 1:
By precisely controlling the pH parameter to remain below pH 4.0 during the integrated purification step, the method achieves effective HCP removal and virus inactivation while preventing antibody aggregation. The low pH conditions selectively affect HCPs and viruses while the antibody's stable structure at this pH protects it from aggregation and maintains its therapeutic properties.
3Manufacturing precision
If current HCP removal processes are applied, then some HCPs are removed, but incomplete removal and inconsistency lead to aggregation and immunogenicity concerns
Solution Approach 1:
The invention establishes a defined pH range (below pH 4.0) that ensures complete and consistent HCP removal across different batches. This parameter control creates reproducible conditions where HCPs are reliably denatured and removed, eliminating the inconsistency and aggregation problems associated with conventional methods.
Solution Approach 2:
The method converts the typically harmful low pH condition into a beneficial tool for complete HCP removal. By intentionally maintaining pH below 4.0, the process exploits the differential pH stability between HCPs (which denature) and the antibody (which remains stable), achieving complete HCP elimination without compromising product quality.
4Manufacturing precision
If increased volumes and additional purification steps are used, then HCPs are removed, but manufacturing costs increase and yield is reduced
Solution Approach 1:
The invention merges HCP removal and virus inactivation into one integrated pH adjustment step performed immediately after affinity chromatography. This consolidation eliminates multiple separate purification steps, prevents product loss through repeated handling and concentration steps, and reduces manufacturing costs while achieving complete HCP removal.
Solution Approach 2:
The method maintains continuous processing by performing pH adjustment and HCP removal in a seamless sequence without interrupting the flow of the antibody preparation. This continuous action prevents product loss that occurs during batch processing and multiple purification steps, thereby maintaining high yield while achieving effective HCP removal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly reduces HCPs to extremely low levels, minimizing aggregation and immunogenicity risks while maintaining product stability and yield, and reducing manufacturing costs by eliminating the need for additional purification steps.
Implementation Method 1
subjecting the protein preparation recombinantly produced in a host cell to an affinity chromatography column
Implementation Method 2
eluting the anti-N3pGlu Aβ antibody from the chromatography column with a buffer comprising a combination of a weak acid and a strong acid
Implementation Method 3
adjusting the pH of the eluate comprising the anti-N3pGlu Aβ antibody to below about pH 4.0
Implementation Method 4
wherein viral inactivation is achieved
Implementation Method 5
subjecting the eluate comprising the anti-N3pGlu Aβ antibody to a depth filter
Data Source
AI summary
The present disclosure relates to methods for reducing host cell protein content in antibody preparation recombinantly produced in a host cell in the manufacturing process of antibodies intended for administration to a patient. The disclosed methods may be performed in order to prepare therapeutic antibody preparations having reduced host cell protein.